MultiPlan Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MPLN research report →
Range $10 – $10
Price Chart
About the company
MultiPlan Corporation, through its various subsidiaries, supplies advanced data analytics and technology-driven solutions to the United States healthcare sector. These services are primarily aimed at optimizing cost management, streamlining payment processes, and ensuring the accuracy of revenue. The company leverages sophisticated algorithms and data-informed insights to deliver analytics-based services that effectively reduce medical expenses.
- CEO
- Melissa Humphrey
- IPO
- 2020
- Employees
- 2,700
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on MPLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $374.98M
- P/E
- -1.43
- PEG
- -0.02
- P/S
- 0.42
- P/B
- -1.40
- EV/EBITDA
- 9.59
- Div Yield
- 0.00%
- Gross Margin
- 44.27%
- Op Margin
- 4.91%
- Net Margin
- -28.46%
- ROE
- 139.56%
- ROIC
- 0.94%
Latest fiscal year · YoY change
- Revenue
- $965.41M+3.7%
- Gross Profit
- $0-100.0%
- Op Income
- $28.77M
- Net Income
- $-284,282,000+82.7%
- EPS
- $-17.30+83.0%
- OCF Growth
- +9.0%
- FCF Growth
- -16.8%
- 52W High
- $38.49
- 52W Low
- $4.80
- 50D MA
- $19.32
- 200D MA
- $13.16
- Beta
- 0.33
- RSI (14)
- 47
- Avg Volume
- 207.99K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Claritev delivered a strong Q2 with revenue, EBITDA, cash flow and bookings all ahead of plan, prompting a full-year raise and reinforcing management’s turnaround thesis.· August 7, 2026
- Q2 revenue was $257.5 million, up 6.6% year over year, and adjusted EBITDA was $155.8 million, or 60.5% of revenue.
- Bookings were strong: management said first-half 2026 ACV reached $74 million, already above all of 2025, and it expects more than $100 million for the full year.
- Full-year guidance was raised to revenue of $1.0 billion to $1.02 billion, adjusted EBITDA of $610 million to $620 million, and free cash flow of $5 million to $15 million.
- Cash generation improved sharply in Q2, with $93 million of operating cash flow, $89.5 million of unlevered free cash flow, and $54.6 million of levered free cash flow.
- Management highlighted momentum in NSA, TPA, and Payment and Revenue Integrity, while noting AI and digital transformation are becoming operating and growth accelerators.
Q2 total revenue was $257.5 million, up 6.6% year over year. Adjusted EBITDA was $155.8 million, or 60.5% of revenue. Operating cash flow was $93 million, up 51% year over year; unlevered free cash flow was $89.5 million, up 24%; and levered free cash flow was $54.6 million, up 49%. On a comparable basis excluding $5.4 million of onetime revenue in Q2 last year, management said total growth was nearly 9%. Full-year 2026 guidance was raised to revenue of $1.0 billion to $1.02 billion, adjusted EBITDA of $610 million to $620 million with margins of approximately 61%, capital spend of $160 million to $170 million, and free cash flow of $5 million to $15 million. Management said it expects at least 50% ACV bookings growth for the full year and more than $100 million of bookings in 2026.
Travis Dalton framed the quarter as evidence that Claritev’s multiyear turnaround is working, saying growth is returning and momentum is building across the business. He emphasized the company’s strategy of horizontal solutions in vertical markets, supported by technology modernization, data architecture, and AI readiness. Dalton also pointed to expanding opportunities in TPA, Medicare Advantage, public sector, and international as signs the growth profile is becoming broader and more durable.
Doug Garis said Q2 outperformed virtually all internal metrics, with revenue, adjusted EBITDA, cash flow, and bookings all ahead of plan. He highlighted $93 million of operating cash flow, $89.5 million of unlevered free cash flow, and $54.6 million of levered free cash flow, noting this was the strongest levered free cash flow quarter in 15 quarters and that DPO and DSO improved by more than 5 days. He also raised full-year revenue guidance to $1.0 billion to $1.02 billion, adjusted EBITDA to $610 million to $620 million, and free cash flow to $5 million to $15 million, while keeping capital spend at $160 million to $170 million.
Analysts focused on whether the Q2 PSA/NSA volume strength was a one-time boost or more structural, and Garis said there was likely some Q2 pull-forward but that the company remains encouraged heading into the second half. Questions also centered on revenue cadence and how bookings convert to revenue; management reiterated that new bookings typically take 2 to 4 quarters to generate first revenue and about 4 quarters to annualize. Analysts asked about AI savings and NSA economics, and management said AI-powered tools are already improving validation and ineligibility assessments, while NSA dynamics and recent rule changes should be net positive over time, though the volume impact in the second half is still being monitored.
The quarter showed accelerating revenue, strong EBITDA, and markedly better cash generation, while bookings momentum suggests the pipeline is translating into future revenue. Management sounded increasingly confident that diversification across TPA, payer, public sector, and Medicare Advantage can support sustained growth, and it believes AI plus the digital transformation can improve both efficiency and win rates.
Management acknowledged that some of the Q2 NSA volume improvement may have been pulled forward, and it is still waiting to see how the revised NSA rules affect volumes in the second half. Revenue conversion is not immediate, with bookings typically taking several quarters to turn into revenue, and management also said it is continuing to invest heavily in sales, marketing, operations, and technology before those newer bookings fully flow through. Q2 network revenue also benefited from comparing against prior-year onetime revenue, and the company expects some mix-driven revenue-per-claim changes to persist.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 33.8%
- Shares Outstanding
- 16.20M
- Float Shares
- 5.47M
of shares held by institutions
60 13F filers
Congressional trading
Senate and House stock disclosures for MPLN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Susie LeeHouse · NV03 | Sell | Nov 12, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 5.27M | ▼ 20.40M |
| Atalaya Capital Management LP | 3.71M | 0 |
| Credit Suisse AG/ | 328.72K | 0 |
| Simplicity Solutions, LLC | 18.01K | ▲ 95 |
Held by 2 ETFs
Biggest fund positions in MPLN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 5, 25 | ARES MANAGEMENT LLC | other | 0 |
| Nov 15, 24 | Kim Michael | other | 0 |
| Nov 15, 24 | Kim Michael | buy | 40,000 |
| Oct 14, 24 | Misencik Tiffani | other | 95,328 |
| Oct 14, 24 | Misencik Tiffani | other | 0 |
| Sep 9, 24 | O'Neil Tara | other | 0 |
| Mar 29, 21 | O'Neil Tara | other | 18,875 |
| Mar 1, 22 | O'Neil Tara | other | 25,221 |
| Aug 7, 24 | Mintz William B. | buy | 197,000 |
| Aug 6, 24 | Mintz William B. | buy | 81,165 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MPLN coverage
Recent articles, reports, and earnings notes.
No research on MPLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MPLN report →ClearNote Health's Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev's National PPO Networks
businesswire.com · Mar 12
Claritev Corporation (MPLN) Q4 2024 Earnings Call Transcript
seekingalpha.com · Feb 25
MultiPlan Corporation (MPLN) Reports Q4 Loss, Misses Revenue Estimates
zacks.com · Feb 25
Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025
businesswire.com · Feb 25
Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design
businesswire.com · Feb 21
MultiPlan Enters New Era and Unveils New Brand, Claritev, Reflecting Company's Transformation and Mission to Support the Healthcare Continuum
businesswire.com · Feb 17
MultiPlan Corporation Announces Fourth Quarter and Full Year 2024 Earnings Conference Call
businesswire.com · Jan 28
MultiPlan Announces Expiration and Results of Exchange Offers and Consent Solicitations for Outstanding Notes and Term Loans with Over 99% Participation of Existing Noteholders and Lenders
businesswire.com · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.